6:35 PM
 | 
Dec 15, 2011
 |  BC Extra  |  Company News

Vertex names new CEO; CF therapy gets Priority Review

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said board member Jeffrey Leiden will succeed Matthew Emmens as president and CEO, effective Feb. 1. Emmens will remain chairman through...

Read the full 107 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >